JP2001511121A5 - - Google Patents

Download PDF

Info

Publication number
JP2001511121A5
JP2001511121A5 JP1998531108A JP53110898A JP2001511121A5 JP 2001511121 A5 JP2001511121 A5 JP 2001511121A5 JP 1998531108 A JP1998531108 A JP 1998531108A JP 53110898 A JP53110898 A JP 53110898A JP 2001511121 A5 JP2001511121 A5 JP 2001511121A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998531108A
Other languages
English (en)
Japanese (ja)
Other versions
JP4216342B2 (ja
JP2001511121A (ja
Filing date
Publication date
Priority claimed from IL11998997A external-priority patent/IL119989A0/xx
Application filed filed Critical
Publication of JP2001511121A publication Critical patent/JP2001511121A/ja
Publication of JP2001511121A5 publication Critical patent/JP2001511121A5/ja
Application granted granted Critical
Publication of JP4216342B2 publication Critical patent/JP4216342B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP53110898A 1997-01-10 1998-01-12 コポリマー1の摂取又は吸入を通じての多発性硬化症の治療 Expired - Lifetime JP4216342B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL119,989 1997-01-10
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (3)

Publication Number Publication Date
JP2001511121A JP2001511121A (ja) 2001-08-07
JP2001511121A5 true JP2001511121A5 (cg-RX-API-DMAC7.html) 2005-09-08
JP4216342B2 JP4216342B2 (ja) 2009-01-28

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53110898A Expired - Lifetime JP4216342B2 (ja) 1997-01-10 1998-01-12 コポリマー1の摂取又は吸入を通じての多発性硬化症の治療

Country Status (18)

Country Link
EP (1) EP0975351B1 (cg-RX-API-DMAC7.html)
JP (1) JP4216342B2 (cg-RX-API-DMAC7.html)
KR (1) KR20000070058A (cg-RX-API-DMAC7.html)
CN (1) CN100528222C (cg-RX-API-DMAC7.html)
AT (1) ATE356608T1 (cg-RX-API-DMAC7.html)
AU (1) AU737287B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI9807076B8 (cg-RX-API-DMAC7.html)
CA (1) CA2277365C (cg-RX-API-DMAC7.html)
CZ (1) CZ297983B6 (cg-RX-API-DMAC7.html)
DE (1) DE69837324T2 (cg-RX-API-DMAC7.html)
EA (1) EA003128B1 (cg-RX-API-DMAC7.html)
HU (1) HU226612B1 (cg-RX-API-DMAC7.html)
IL (2) IL119989A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ336690A (cg-RX-API-DMAC7.html)
PL (1) PL193300B1 (cg-RX-API-DMAC7.html)
SK (1) SK284029B6 (cg-RX-API-DMAC7.html)
WO (1) WO1998030227A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA98214B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003521448A (ja) * 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
CA2375874A1 (en) * 1999-06-04 2000-12-14 Chris Polman Use of riluzole for the treatment of multiple sclerosis
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1459065B1 (en) 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
JP2007521249A (ja) * 2003-01-24 2007-08-02 エラン ファーマシューティカルズ,インコーポレイテッド 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649537B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Similar Documents

Publication Publication Date Title
JP2000509912A5 (cg-RX-API-DMAC7.html)
JP2000509637A5 (cg-RX-API-DMAC7.html)
JP2000509635A5 (cg-RX-API-DMAC7.html)
JP2000509942A5 (cg-RX-API-DMAC7.html)
JP2000507042A5 (cg-RX-API-DMAC7.html)
JP2000510751A5 (cg-RX-API-DMAC7.html)
JP2000514276A5 (cg-RX-API-DMAC7.html)
JP2001517080A5 (cg-RX-API-DMAC7.html)
JP2000509587A5 (cg-RX-API-DMAC7.html)
JP2000507433A5 (cg-RX-API-DMAC7.html)
JP2000508866A5 (cg-RX-API-DMAC7.html)
JP2000510793A5 (cg-RX-API-DMAC7.html)
JP2000508022A5 (cg-RX-API-DMAC7.html)
JP2000508841A5 (cg-RX-API-DMAC7.html)
JP2002502564A5 (cg-RX-API-DMAC7.html)
JP2000508680A5 (cg-RX-API-DMAC7.html)
JP2000509804A5 (cg-RX-API-DMAC7.html)
JP2000509755A5 (cg-RX-API-DMAC7.html)
JP2000510247A5 (cg-RX-API-DMAC7.html)
JP2000510969A5 (cg-RX-API-DMAC7.html)
JP2000508102A5 (cg-RX-API-DMAC7.html)
JP2000509818A5 (cg-RX-API-DMAC7.html)
JP2000509520A5 (cg-RX-API-DMAC7.html)
JP2000507434A5 (cg-RX-API-DMAC7.html)
JP2000508880A5 (cg-RX-API-DMAC7.html)